Could FDA-evaluated tissue chips succeed where animal testing falls short?

Researchers at the University of Rochester have achieved a key FDA milestone by having their tissue chip technology accepted into the FDA's ISTAND pilot program. This platform uses human cell-based chips to predict immune-related toxicities of cancer immunotherapies more accurately than animal testing, aiming to improve and potentially replace preclinical drug safety studies.

This Wire brief sits within Fusion42's coverage of Healthtech Infrastructure.